Treatment of acute myeloid leukemia patients aged more than 75 years: Results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG)
Authors:
- 1 January 2006
- journal article
- clinical trial
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 47 (10) , 2062-2069
Abstract
The feasibility and effects of combination chemotherapy for very elderly patients with acute myeloid leukemia was examined in 65 patients (including previous myelodysplastic syndrome) aged 76 years or morewith a performance status of 0 – 3. Induction chemotherapy was performed with 30 mg/m2 daunorubicin on days 1 – 3, 150 mg/m2 behenoyl cytosine arabinoside on days 1 – 7, and 70 mg/m2 6-mercaptopurine with 300 mg allopurinol taken orally on days 1 – 7 (BHAC-DM). The complete remission (CR) rate was 38.5%, whereas overall survival at 2 and 5 years was 22.0% and 4.7%, respectively. Two- and 5-year survival of CR patients was 41.8% and 11.2%, respectively. The relapse rate of the 25 CR patients was 64.0% and disease-free survival at 2 and 5 years was 21.0% and 11.2%, respectively. The therapy-related mortality rate at induction was 13.8%. BHAC-DM is feasible and effective for selected very elderly acute myeloid leukemia patients.Keywords
This publication has 21 references indexed in Scilit:
- Disease biology rather than age is the most important determinant of survival of patients ≥ 60 years with acute myeloid leukemia treated with uniform intensive therapyCancer, 2005
- The benefit of induction chemotherapy in patients age ≥ 75 yearsCancer, 2004
- A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology GroupBlood, 2004
- Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago seriesBlood, 2003
- Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group studyBlood, 2002
- Long‐term follow‐up of patients ≥60 yr old with acute myeloid leukaemia treated with intensive chemotherapyEuropean Journal of Haematology, 2002
- Therapy Related Leukemias: Susceptibility, Prevention and TreatmentLeukemia & Lymphoma, 2001
- Treatment of newly‐diagnosed acute myelogenous leukaemia in patients aged 80 years and aboveBritish Journal of Haematology, 1996
- Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patientsBritish Journal of Haematology, 1994
- ACUTE MYELOID LEUKAEMIA IN THE ELDERLY: BIOLOGY AND TREATMENTBritish Journal of Haematology, 1993